Amgen Inc.
A biotechnology company that makes medicines for serious illnesses, including the bone-strengthening drug Prolia, the cholesterol-lowering injection Repatha, and the psoriasis treatment Otezla, sold to patients and doctors worldwide. It was founded in 1980 in Thousand Oaks, California, as Applied Molecular Genetics, a name later shortened to "Amgen." Its first CEO famously ran the company from a small trailer so scientists could use the office space, and early experiments included trying to extract oil from shale and accelerate chicken growth.
Granted 174.6K
Granted 68.8K · Sold 54.8K
Granted 17.0K · Sold 6.9K
Granted 15.7K
Granted 15.0K
Granted 13.3K
Granted 3.3K
Granted 665
Granted 665
Granted 665
Granted 1.1K
Granted 665
Granted 4.4K
Granted 2.4K · Sold 890
Granted 665
Granted 665
Granted 5.6K · Sold 4.4K
Granted 989.8
Granted 963.25
Granted 665
Granted 1.4K · Sold 1.0K
Granted 665
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Bradway Robert AChairman, CEO and President, Director · 9 transactions | — | 655.2K | 174.6K | — | — |
| Santos EstebanEVP, Operations · 11 transactions | +8.4% | 83.8K | 68.8K | — | 54.8K |
| Gordon MurdoEVP, Global Commercial Ops · 8 transactions | +2.5% | 51.2K | 17.0K | — | 6.9K |
| Griffith Peter H.EVP & CFO · 7 transactions | +18.7% | 50.1K | 15.7K | — | — |
| Reese David MEVP & Chief Technology Officer · 9 transactions | +0.3% | 42.3K | 15.0K | — | — |
| Graham Jonathan PEVP & Gen. Counsel & Sec. · 7 transactions | +18.5% | 39.7K | 13.3K | — | — |
| Bradner James E.EVP, Research and Development · 5 transactions | +0.9% | 30.0K | 3.3K | — | — |
| Eckert RobertDirector · 1 transaction | +4.9% | 26.3K | 665 | — | — |
| Jacks TylerDirector · 1 transaction | +6.3% | 18.3K | 665 | — | — |
| Kullman Ellen JamisonDirector · 1 transaction | +7.9% | 14.5K | 665 | — | — |
| Holley Charles MDirector · 3 transactions | +10.4% | 14.1K | 1.1K | — | — |
| Garland Greg C.Director · 1 transaction | +5% | 13.8K | 665 | — | — |
| Miller DerekSVP, Human Resources · 7 transactions | +22.1% | 12.4K | 4.4K | — | — |
| Khosla RachnaSVP, Business Development · 9 transactions | +2.8% | 8.4K | 2.4K | — | 890 |
| Druker BrianDirector · 1 transaction | +10.9% | 8.4K | 665 | — | — |
| Austin Wanda MDirector · 1 transaction | +9% | 8.0K | 665 | — | — |
| Grygiel Nancy A.SVP & CCO · 12 transactions | +1.7% | 7.4K | 5.6K | — | 4.4K |
| Ishrak OmarDirector · 3 transactions | +17.9% | 7.4K | 989.8 | — | — |
| Drake Michael VDirector · 3 transactions | +22.9% | 5.8K | 963.25 | — | — |
| Miles Amy EDirector · 1 transaction | +16.5% | 5.6K | 665 | — | — |
| Busch Matthew C.VP, Finance & CAO · 9 transactions | -5.3% | 4.3K | 1.4K | — | 1.0K |
| Klotman Mary E.Director · 1 transaction | +44.7% | 2.2K | 665 | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last year: -67.9K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.